

Dear Author,

Here are the final proofs of your article. Please check the proofs carefully.

Please note that at this stage you should only be checking for errors introduced during the production process. Please pay particular attention to the following when checking the proof:

- Author names. Check that each author name is spelled correctly, and that names appear in the correct order of first name followed by family name. This will ensure that the names will be indexed correctly (for example if the author's name is 'Patel, J. ', she will be cited as ' Jane Patel ').
- Affiliations. Check that all authors are cited with the correct affiliations, that the author who will receive correspondence has been identified with an asterisk (*), and that all equal contributors have been identified with a well sign (#).
- Ensure that the main text is complete.
- Check that figures, tables and their legends are included and in the correct order.
- Look to see that queries that were raised during copy-editing or typesetting have been resolved.
- Confirm that all web links are correct and working.
- Ensure that special characters and equations are displaying correctly.
- Check that additional or supplementary files can be opened and are correct.

Changes in scientific content cannot be made at this stage unless the request has already been approved. This includes changes to title or authorship, new results, or corrected values.

How to return your corrections

Returning your corrections via email:

- Annotate the proof PDF with your corrections.
- Remember to include the journal title, manuscript number, and your name when sending your response via email.

After you have submitted your corrections, you will receive email notification from our production team that your article has been published in the final version. All changes at this stage are final. We will not be able to make any further changes after publication.

Kind regards,



An immune stress test for resilience to aging: Pneumococcal vaccine response

Ryan Oveson^a, Zhou Jiang^a, Michali Izhaky^a, Kavita Sharma^a, Warren C. Ladiges^{a,*}

^a Department of Comparative Medicine, School of Medicine, University of Washington, Seattle, WA, USA.

Abstract

The idea that the degree of response to physical stress in early life can be used to measure health in later life is a novel approach to better define resilience to aging. To investigate this, middle-age (15 months) mice were stressed by vaccination with a commercial pneumococcal vaccine (Prevnar 13), and 30 days later separated into a high antibody response group and a low antibody response group using Elisa to detect IgG serum antibody levels. After 4 months, mice were evaluated for physiological performance and learning ability. The high antibody response group was able to stay on a rotating rod longer than the low antibody response group and were more quickly able to find the escape hole in a spatial navigation learning task. This observation suggests Prevnar 13 antibody response in midlife could be a useful stress test to predict healthy aging.

Keywords: Resilience to aging, immune stress test, prevnar 13 vaccine, elisa antibody titers, aging mice

Resilience to aging is a well-recognized biological event that precedes age-related decline in physiological function and is defined as an organism's ability to respond to physical stressors with increasing age [1-2]. However, predictive factors of physical resilience for maintaining optimum health with increasing age have not been well characterized. One type of stress on the immune system is vaccination, which can be measured by the degree of antibody response. As a preclinical model to investigate this approach, 15-month old C57BL/6 mice were vaccinated with a 1:10 dilution of Prevnar 13 (Pfizer), a commonly used pneumococcal vaccine in older people. Blood was collected 30 days after vaccination and a Prevnar 13-specific mouse IgG antibody ELISA kit (Invitrogen, Thermo Fisher Scientific) was used to quantify serum IgG antibody levels. Five months following vaccination, mice were tested for physiological performance in a spatial navigation task for learning ability and a rotating rod for motor coordination. Mice could be grouped into high responders and low responders based on the strength of detecting IgG antibody levels to the Prevnar 13 vaccine (Figure 1).




Figure 1. Mice injected subcutaneously with a 1:10 dilution of Prevnar 13 vaccine could be separated into high and low responders based on strength of Elisa antibody levels 30 days after vaccination, N = 25. The cutoff between high and low responders was 0.562 absorbance.

* Corresponding author: Warren Ladiges

Mailing address: Department of Comparative Medicine, School of Medicine, University of Washington, Seattle, WA, USA.

Email: wladiges@uw.edu

Received: 31 September 2020 / Accepted: 06 September 2020




Figure 2. High Pevnar 13 antibody response mice showed an increased run time on the rotating rod test compared to the low antibody response group, N = 8-10 per cohort, $p \leq 0.05$.

Five months following Pevnar 13 vaccination, mice in the high IgG antibody response group, as determined one month after vaccination, had a longer run time on the rotarod test (Figure 2) and a faster escape time in the spatial navigation learning task (Figure 3) compared to mice in the low antibody response group.

These observations in mice suggest that antibody levels to Pevnar 13, as measured by Elisa, could serve as a model for predicting age-related resilience. The translational relevance is potentially impactful because older adults are vaccinated with Pevnar 13, and retrospective and prospective studies could be developed to investigate the correlation of serum antibody levels with a variety of aging parameters.




Figure 3. High Pevnar 13 antibody response mice showed a lower R2 slope for escape times in the box maze compared to the low antibody response group, N = 8-10 per cohort. $p \leq 0.05$ for trial 3.

Declaration

Acknowledgments: Supported by a grant from the National Institute on Aging, R56AG058543 (W. Ladiges, PI).

Conflict of Interest: The authors declare that they have no conflict of interest.

References

1. Kennedy B K, Berger S L, Brunet A, et al. Geroscience: linking aging to chronic disease. *Cell*, 2014, 159(4): 709-713.
2. Siu AL, Kohanski R. Geroscience and the trans-NIH geroscience interest group, GSIG. 2017.

Cite this article as: Ryan Oveson, Zhou Jiang, Michali Izhaky, et al. An immune stress test for resilience to aging: Pneumococcal vaccine response [J]. *Aging Pathobiology and Therapeutics*, 2020, 2(3): xx-xx.

Author Query Form

Dear Author,

During the copy-editing of your paper, the following queries arose.

Please refer to the query reference call out numbers in the page proofs and respond to each by marking the necessary comments using the PDF annotation tools.

Please remember illegible or unclear comments and corrections may delay publication.

Many thanks for your assistance.

QueryReference	Query	Remark
Q1	Author: Please confirm that given names and surnames/family names have been identified correctly.	
Q2	Affiliations: Please check if the affiliations are presented correctly.	
Q3	Corresponding author: Please check if the information are presented correctly.	
Q4	Please check if the reference is correct?	